Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients.
This is an extended open study of oral prophylactic treatment with egg yolk antibodies against Pseudomonas aeruginosa, Anti-Pseudomonas IgY, of 17 Swedish patients with cystic fibrosis. They have been on prophylactic IgY treatment for up to 12 years and altogether for 114 patient years. A group of 23 Danish CF patients served as control. There has been a total absence of adverse events. Only 29 cultures have been positive for P. aeruginosa (cultures after chronic colonization not included), that is, 2.3/100 treatment months compared to 7.0/100 months in the control group (P = 0.028). In the IgY treated group only one pair of siblings (2/17) has been chronically colonized with P. aeruginosa compared to seven patients (7/23) in the control group. Atypical mycobacteria, S. maltophilia, A. xylosoxidans, and A. fumigatus have appeared only sporadically. There have been no cultures positive for B. cepacia. There was no decrease in pulmonary functions (P = 0.730) within the IgY group. Body mass index values were normal or close to normal for all IgY treated patients. In conclusion, Anti-Pseudomonas IgY has great potential to prevent P. aeruginosa infections.
Nilsson
Elin
E
Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden. elin.nilsson@medsci.uu.se
Larsson
Anders
A
Olesen
Hanne V
HV
Wejåker
Per-Erik
PE
Kollberg
Hans
H
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications*; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology*; D055815:Young Adult
C016512:IgY; D007136:Immunoglobulins